X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs DR. REDDYS LAB - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD DR. REDDYS LAB BIOCON LTD/
DR. REDDYS LAB
 
P/E (TTM) x 75.1 34.3 219.0% View Chart
P/BV x 7.1 3.4 210.2% View Chart
Dividend Yield % 0.2 0.8 21.8%  

Financials

 BIOCON LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
DR. REDDYS LAB
Mar-17
BIOCON LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1623,397 34.2%   
Low Rs4832,560 18.8%   
Sales per share (Unadj.) Rs194.6856.5 22.7%  
Earnings per share (Unadj.) Rs34.478.0 44.1%  
Cash flow per share (Unadj.) Rs48.3139.9 34.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.10.7 18.1%  
Book value per share (Unadj.) Rs241.9739.8 32.7%  
Shares outstanding (eoy) m200.00165.74 120.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.23.5 121.5%   
Avg P/E ratio x23.938.2 62.6%  
P/CF ratio (eoy) x17.021.3 80.0%  
Price / Book Value ratio x3.44.0 84.4%  
Dividend payout %2.925.7 11.3%   
Avg Mkt Cap Rs m164,440493,632 33.3%   
No. of employees `0009.222.7 40.7%   
Total wages/salary Rs m7,47031,068 24.0%   
Avg. sales/employee Rs Th4,213.96,259.0 67.3%   
Avg. wages/employee Rs Th809.01,369.8 59.1%   
Avg. net profit/employee Rs Th745.2569.7 130.8%   
INCOME DATA
Net Sales Rs m38,911141,961 27.4%  
Other income Rs m1,5711,715 91.6%   
Total revenues Rs m40,482143,676 28.2%   
Gross profit Rs m9,79524,722 39.6%  
Depreciation Rs m2,77210,266 27.0%   
Interest Rs m260634 41.0%   
Profit before tax Rs m8,33415,537 53.6%   
Minority Interest Rs m1630-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6162,965 54.5%   
Profit after tax Rs m6,88112,921 53.3%  
Gross profit margin %25.217.4 144.5%  
Effective tax rate %19.419.1 101.6%   
Net profit margin %17.79.1 194.3%  
BALANCE SHEET DATA
Current assets Rs m40,47796,837 41.8%   
Current liabilities Rs m16,78384,199 19.9%   
Net working cap to sales %60.98.9 684.0%  
Current ratio x2.41.2 209.7%  
Inventory Days Days6073 81.2%  
Debtors Days Days8398 84.8%  
Net fixed assets Rs m45,073102,552 44.0%   
Share capital Rs m1,000829 120.6%   
"Free" reserves Rs m47,377121,792 38.9%   
Net worth Rs m48,377122,621 39.5%   
Long term debt Rs m21,0825,449 386.9%   
Total assets Rs m93,942218,165 43.1%  
Interest coverage x33.125.5 129.6%   
Debt to equity ratio x0.40 980.7%  
Sales to assets ratio x0.40.7 63.7%   
Return on assets %7.66.2 122.3%  
Return on equity %14.210.5 135.0%  
Return on capital %12.612.9 97.7%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m12,98881,670 15.9%   
Fx outflow Rs m7,89926,355 30.0%   
Net fx Rs m5,08955,315 9.2%   
CASH FLOW
From Operations Rs m6,40021,444 29.8%  
From Investments Rs m-4,985-18,404 27.1%  
From Financial Activity Rs m-1,775-3,692 48.1%  
Net Cashflow Rs m-473-1,144 41.3%  

Share Holding

Indian Promoters % 40.4 25.5 158.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.4 155.6%  
FIIs % 10.7 35.3 30.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 19.9 15.3 130.1%  
Shareholders   109,995 75,885 144.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 19, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - PANACEA BIOTECH COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS